Searle/Pfizer Celebrex
Celecoxib NDA for treatment of familial adenomatous polyposis will receive six-month priority review; new indication for the COX-2 inhibitor was submitted as early as the last week in June
Celecoxib NDA for treatment of familial adenomatous polyposis will receive six-month priority review; new indication for the COX-2 inhibitor was submitted as early as the last week in June